The leveraged finance and private equity communities came together on 29 January 2025 for the inaugural Leveraged Finance Fights Melanoma (LFFM) London benefit and cocktail party at The National ...

But all that came to a halt when she discovered a raised bump on her right leg. “It was about the size of this thumbnail,” she told Ivanhoe. Doctors said it was melanoma… an often-aggressive ...

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares.

Shares of Replimune Group, Inc. (NASDAQ: NASDAQ:REPL) surged 17% following the announcement that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...